Zolidronate

# Zolidronate ## Overview - **Classification**: Bisphosphonate (nitrogen-containing) - **Mechanism**: Potent inhibitor of osteoclastic bone resorption. Binds to bone hydroxyapatite, inhibits farnesyl pyrophosphate synthase in osteoclasts, leading to osteoclast apoptosis and reduced bone turnover. ## Primary Indications 1. **Hypercalcemia of Malignancy (HCM)** - Reduction of serum calcium in cancer patients. 2. **Multiple Myeloma and Bone Metastases** - Prevention of skeletal-related events (SREs) in patients with advanced malignancies. 3. **Paget's Disease of Bone** - Treatment of moderate to severe Paget's disease. 4. **Osteoporosis** - Treatment and prevention of postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced osteoporosis. ## Adult Dosing ### Standard Dosing **Hypercalcemia of Malignancy (HCM)** - **Dose**: **4 mg** - **Frequency**: Single dose; may be repeated after **7 days** if needed. - **Route**: Intravenous (IV) infusion over **at least 15 minutes**. - **Special Considerations**: Ensure patient is well-hydrated before administration. **Multiple Myeloma & Bone Metastases from Solid Tumors** - **Dose**: **4 mg** - **Frequency**: Every **3 to 4 weeks**. - **Route**: IV infusion over **at least 15 minutes**. - **Duration**: Long-term as clinically indicated. **Paget's Disease of Bone** - **Dose**: **5 mg** - **Frequency**: Single dose. May be repeated after **1 year** if relapse occurs. - **Route**: IV infusion over **at least 15 minutes**. **Osteoporosis (Treatment & Prevention)** - **Dose**: **5 mg** - **Frequency**: **Once yearly**. - **Route**: IV infusion over **at least 15 minutes**. ### Dose Adjustments - **Renal Impairment**: * **HCM**: No dose adjustment needed. * **Multiple Myeloma/Bone Metastases**: * Baseline CrCl **60 mL/min or higher**: **4 mg**. * Baseline CrCl **50-60 mL/min**: **3.5 mg**. * Baseline CrCl **40-49 mL/min**: **3.5 mg**. * Baseline CrCl **30-39 mL/min**: **3 mg**. * CrCl **less than 30 mL/min**: Not recommended to initiate. For ongoing treatment, discontinue if CrCl drops below **30 mL/min**. * **Paget's Disease/Osteoporosis**: Contraindicated if CrCl is **less than 35 mL/min**. - **Hepatic Impairment**: No specific dose adjustment recommended. - **Elderly Patients**: No specific dose adjustment needed based on age alone, but monitor renal function carefully. ## Pediatric Dosing Zolidronate is generally not recommended for routine pediatric use outside of specific circumstances. ### Adolescents (13-18 years) - **Hypercalcemia of Malignancy (HCM)**: Limited data suggest **4 mg** IV infusion over **at least 15 minutes**, similar to adult dosing. Use with caution. - **Paget's Disease**: **5 mg** IV infusion over **at least 15 minutes**, similar to adult dosing. Use with caution in this age group. - **Osteogenesis Imperfecta (OI)**: (Off-label use) * **Dose**: Typically **0.025 mg/kg** to **0.05 mg/kg** per infusion. * **Frequency**: Every **3 to 6 months**. * **Maximum**: Not to exceed **4 mg** per infusion. * **Special Notes**: Requires careful monitoring of calcium, phosphate, and renal function. Calcium and vitamin D supplementation is essential. ### Children (1-12 years) & Infants (1-12 months) & Neonates (0-28 days) - **General**: Routine use for osteoporosis is not recommended. - **Osteogenesis Imperfecta (OI)**: (Off-label use) * **Dose**: Often **0.025 mg/kg** to **0.05 mg/kg** IV. * **Frequency**: Every **3 to 6 months**. * **Maximum**: Not to exceed **4 mg** per infusion. * **Special Notes**: Critical to ensure adequate calcium and vitamin D status. Close monitoring for hypocalcemia and renal function is vital. Infusion rates must be slow (e.g., over **60 minutes** for smaller children). ## Safety Information ### Contraindications - **Absolute**: Hypocalcemia - **Absolute**: Severe renal impairment (CrCl <35 mL/min for Paget's/Osteoporosis indications) - **Absolute**: Pregnancy and Lactation - **Absolute**: Hypersensitivity to zolendronic acid or other bisphosphonates. ### Common Adverse Effects - **Very Common (>10%)**: Fever, flu-like symptoms (arthralgia, myalgia, headache), fatigue, nausea, bone pain. - **Common (1-10%)**: Anemia, constipation, diarrhea, vomiting, rash, cough, dyspnea, peripheral edema, hypophosphatemia, hypomagnesemia. - **Serious but Rare**: Osteonecrosis of the jaw (ONJ), atypical femoral fracture (AFF), severe renal impairment, ocular inflammation (uveitis, scleritis), severe musculoskeletal pain, atrial fibrillation (with osteoporosis indication). ### Key Drug Interactions - **Aminoglycosides/Loop Diuretics**: Increased risk of hypocalcemia. Monitor calcium levels. - **Nephrotoxic Drugs (e.g., NSAIDs, cisplatin)**: Concurrent use may increase risk of renal deterioration. Avoid if possible, or monitor renal function closely. - **Thalidomide/Corticosteroids**: May increase risk of ONJ in cancer patients. - **Dextrans/Aminoglycosides**: Zoledronic acid may potentiate their renal effects if used concurrently. ## Monitoring & Follow-up - **Before Treatment**: * Serum creatinine (CrCl calculation) * Serum calcium, phosphate, magnesium (correct hypocalcemia prior to infusion) * Dental examination (for patients at risk of ONJ, especially cancer patients). - **During Treatment**: * Renal function (CrCl) before each dose for cancer indications. * Serum calcium, phosphate, magnesium levels periodically, especially after initial dose. * Monitor for signs/symptoms of ONJ (jaw pain, swelling, non-healing sores) and AFF (new thigh/groin pain). * Maintain good oral hygiene. - **Clinical Signs**: * Symptoms of hypocalcemia (e.g., paresthesias, muscle spasms, tetany). * Severe bone, joint, or muscle pain. * Ocular pain or vision changes. ## Clinical Pearls - 💡 **Hydration is Key**: Always ensure patients are adequately hydrated prior to and during administration, especially for HCM, to reduce risk of renal toxicity. - 💡 **Calcium & Vitamin D**: Ensure adequate daily calcium and vitamin D intake (via diet or supplements) for all patients, especially those treated for osteoporosis or Paget's. - 💡 **Slow Infusion**: Infuse over **at least 15 minutes** to minimize risk of renal impairment. Faster infusions increase risk. - 💡 **Report Pain**: Counsel patients to report any new or unusual pain in the thigh, hip, or groin as this could be an atypical femoral fracture. - 💡 **Dental Health**: Advise patients on good oral hygiene and to report any jaw pain or swelling. A dental check-up before starting treatment is recommended for high-risk patients. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.